ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

F. Cardoso a, , A. Costa b, , L. Norton , E. Senkus , M. Aapro , F. Andr e , C.H. Barrios , J. Bergh , L. Biganzoli , K.L. Blackwell , M.J. Cardoso , T. Cufer , N. El Saghir , L. Fallowfield , D. Fenech , P. Francis , K. Gelmon , S.H. Giordano , J. Gligorov , A. Goldhirsch , N. Harbeck , N. Houssami , C. Hudis , B. Kaufman , I. Krop , S. Kyriakides , U.N. Lin , M. Mayer , S.D. Merjaver , E.B. Nordstr€ om , O. Pagani , A. Partridge , F. Penault-Llorca , M.J. Piccart , H. Rugo , G. Sledge , C. Thomssen , L. van’t Veer , D. Vorobiof , C. Vrieling , N. West , B. Xu , E. Winer z

[1]  P. Neven,et al.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Fiscella,et al.  Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[4]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[5]  Allan Donner,et al.  Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial , 2014, The Lancet.

[6]  X. Pivot,et al.  Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. , 2014, Breast.

[7]  M. Piccart,et al.  1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2 , 2014 .

[8]  S. Sundar,et al.  'IS IT MY LAST CHRISTMAS DINNER?' SURVIVAL OF CANCER PATIENTS HAVING PALLIATIVE CHEMOTHERAPY DURING CHRISTMAS PERIOD , 2014, BMJ Supportive & Palliative Care.

[9]  J. Lovato,et al.  Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  S. Barni,et al.  The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.

[11]  P. Fasching,et al.  Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma , 2014, Breast Cancer Research and Treatment.

[12]  R. Gelber,et al.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. , 2014, The Lancet. Oncology.

[13]  F. Cardoso,et al.  First international consensus guidelines for breast cancer in young women (BCY1). , 2014, Breast.

[14]  Marisa C. Jenkins,et al.  Combination versus sequential single agent chemotherapy for metastatic breast cancer. , 2013, The Cochrane database of systematic reviews.

[15]  S. Kelsey,et al.  Abstract S2-03: Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01) , 2013 .

[16]  M. Piccart,et al.  Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis , 2013, Advances in Therapy.

[17]  F. Cardoso,et al.  An update on male breast cancer and future directions for research and treatment. , 2013, European journal of pharmacology.

[18]  Felicia Marie Knaul,et al.  Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. , 2013, Breast.

[19]  B. Thompson,et al.  Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. , 2013, Breast.

[20]  A. Howell,et al.  Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. , 2013, The Lancet. Oncology.

[21]  E. Winer,et al.  International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. , 2013, Breast.

[22]  M. Rezai,et al.  A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). , 2013 .

[23]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[24]  F. Wright,et al.  What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer? , 2013, Current oncology.

[25]  Farhat Yaqub.  T-DM1 for HER2-positive metastatic breast cancer. , 2013, The Lancet. Oncology.

[26]  W. Woodward,et al.  Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy , 2013, Radiation Oncology.

[27]  J. Wanders,et al.  Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes , 2012 .

[28]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[29]  S. Verma,et al.  Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[30]  J. Albanell,et al.  A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study , 2012, Breast Cancer Research and Treatment.

[31]  T. Shien,et al.  A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. , 2012, Japanese journal of clinical oncology.

[32]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[33]  M. Desilvio,et al.  Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC) , 2012 .

[34]  J. Bergh,et al.  When to order a biopsy to characterise a metastatic relapse in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Barni,et al.  Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression , 2012, Medical Oncology.

[37]  W. Woodward,et al.  Inflammatory breast cancer: what we know and what we need to learn. , 2012, The oncologist.

[38]  J. Baselga,et al.  Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Whelan,et al.  Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Hudis,et al.  1st International consensus guidelines for advanced breast cancer (ABC 1). , 2012, Breast.

[41]  Y. M. van der Linden,et al.  SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation , 2012, BMC Surgery.

[42]  M. Brennan,et al.  Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. , 2012, Breast.

[43]  H. Iwata,et al.  Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[44]  Laura Biganzoli,et al.  Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). , 2012, The Lancet. Oncology.

[45]  K. Gelmon,et al.  Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[47]  Jorge Ernesto González,et al.  Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells , 2012, Cancer biology & therapy.

[48]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[49]  F. Cardoso,et al.  The EUSOMA recommendations for the management of young women with breast cancer , 2012 .

[50]  E. Bastiaannet,et al.  Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  Val Gebski,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Bellon,et al.  ACR Appropriateness Criteria® Locally Advanced Breast Cancer , 2011, The breast journal.

[54]  M. Lesperance,et al.  Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Ernst,et al.  The role of surgery in metastatic breast cancer. , 2011, European journal of cancer.

[56]  J. Niland,et al.  Surgery of the primary tumor does not improve survival in stage IV breast cancer , 2011, Breast Cancer Research and Treatment.

[57]  J. Olson,et al.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Bergh,et al.  Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden , 2011, Breast Cancer Research and Treatment.

[59]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Piccart,et al.  Pattern of care in locally advanced breast cancer: focus on local therapy. , 2011, Breast.

[61]  Marilys Corbex,et al.  Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. , 2011, Breast.

[62]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[63]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Khan.  Stage IV Breast Cancer in the Era of Targeted Therapy: Does Surgery of the Primary Tumor Matter? , 2011 .

[66]  S. Brucker,et al.  Re-surgery and chest wall re-irradiation for recurrent breast cancer - a second curative approach , 2011, BMC Cancer.

[67]  M. Dewhirst,et al.  Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[68]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[69]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  R. Shi,et al.  Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. , 2010, Breast.

[71]  A. Shibata,et al.  Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair , 2010, Molecular Cancer Therapeutics.

[72]  Ethan Basch,et al.  The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.

[73]  L. Carey,et al.  Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. , 2010, International journal of radiation oncology, biology, physics.

[74]  M. Rosenzweig,et al.  Patient Navigation in Breast Cancer: A Systematic Review , 2010, Cancer nursing.

[75]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Lubiński,et al.  Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Lubiński,et al.  Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  G. Vlastos,et al.  Loco-regional treatment in metastatic breast cancer patients: Is there a survival benefit? , 2010, Breast Cancer Research and Treatment.

[79]  F. Cardoso.  Metastatic breast cancer patients: the forgotten heroes! , 2009, Breast.

[80]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.

[81]  M. Mumber,et al.  Patient navigation through the cancer care continuum: an overview. , 2009, Journal of oncology practice.

[82]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .

[83]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[84]  D. Dalley,et al.  Breast Cancer in Men—Should Aromatase Inhibitors Become First‐Line Hormonal Treatment? , 2008, The breast journal.

[85]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  J. Niland,et al.  Selecting High Priority Quality Measures For Breast Cancer Quality Improvement , 2008, Medical care.

[87]  Tomasz Burzykowski,et al.  Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  M. Namer,et al.  Prognostic factors in 1038 women with metastatic breast cancer , 2008 .

[89]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[90]  M. Ellis,et al.  Letrozole in the neoadjuvant setting: the P024 trial , 2007, Breast Cancer Research and Treatment.

[91]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[92]  J. Griggs,et al.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  E. Winer,et al.  Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.

[94]  A. Buzdar,et al.  Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer , 2006, Cancer.

[95]  George D Wilson,et al.  Biologic basis for combining drugs with radiation. , 2006, Seminars in radiation oncology.

[96]  H. Freeman.  Patient navigation: a community centered approach to reducing cancer mortality. , 2006, Journal of cancer education : the official journal of the American Association for Cancer Education.

[97]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[98]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C. Osborne,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma , 2005, Cancer.

[100]  Zeljko Vujaskovic,et al.  Randomized trial of hyperthermia and radiation for superficial tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  M. Brennan,et al.  Locally advanced and inflammatory breast cancer. , 2005, Australian family physician.

[103]  M. Rivard,et al.  Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  R. Rouzier,et al.  Breast cancer with synchronous metastases: trends in survival during a 14-year period. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Howell,et al.  Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials , 2004 .

[106]  S. Giordano,et al.  Update on locally advanced breast cancer. , 2003, The oncologist.

[107]  M. Piccart,et al.  Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  A. Milla-Santos,et al.  Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer: A Prospective, Randomized, Phase III Study , 2003, American journal of clinical oncology.

[109]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  H. Burger,et al.  Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines , 2002, British Journal of Cancer.

[111]  Douglas B. Evans,et al.  Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? , 2001, International journal of radiation oncology, biology, physics.

[112]  A. Buzdar,et al.  Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.

[113]  H. Burger,et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[115]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  H. Ishitsuka,et al.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Tepper,et al.  Fluoropyrimidine-Radiation Interactions in Cells and Tumors. , 1997, Seminars in radiation oncology.

[120]  E. Rutgers,et al.  Chest wall resection in the treatment of locally recurrent breast carcinoma , 1997, Cancer.

[121]  D Machin,et al.  Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. , 1996, International journal of radiation oncology, biology, physics.

[122]  F. Cavalli,et al.  First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  J. Mitchell,et al.  In vitro studies of Taxol as a radiation sensitizer in human tumor cells. , 1994, Journal of the National Cancer Institute.

[124]  D. Schultz,et al.  The results of radiation therapy for isolated local regional recurrence after mastectomy. , 1991, International journal of radiation oncology, biology, physics.

[125]  J. Broadhead,et al.  WHO consensus statement. , 1990, The British journal of psychiatry : the journal of mental science.

[126]  P. Siiteri,et al.  Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. , 1974, The Journal of clinical endocrinology and metabolism.